Overview

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to explore the efficacy and safety of the weekly intraocular pressure change of the TFC-003 group and the dorzolamid/timolol combination group in patients with primary open-angle glaucoma or ocular hypertension.

Phase:

Phase 2

Details

Lead Sponsor:

Kukje Pharma

Treatments:

Ophthalmic Solutions